TABLE 4.

Cervical Intraepithelial Neoplasia 2 or Higher and CIN 3 or Higher 3, 5, 10-Year Risks Comparing SGTP With GS

Kitchener et al.51 (2014) and Gilham et al.50 (2019)	Pooled HPV persistent	SGTP	GS	HPV(+), then HPV(−) as referent	HPV(−), then HPV(−) as referent
≥CIN 2 three-year risk51	12.9%	21.0%	6.2	0.59%	0.02%
≥CIN 3 three-year risk51	7.0%	13.5%	1.7%	0.17%	0%
≥CIN 3 five-year CIR; NILM50	7.0 (3.9–12.2)	11.3 (6.5–19.5)	0	0.13 (0.02–0.90)	0.05 (0.02–0.11)
≥CIN 3 ten-year CIR; NILM50	8.9 (5.4–14.5)	13.4 (8.0–22.0)	1.7 (0.2–11.3)	0.26 (0.06–1.03)	0.09 (0.05–0.17)
≥CIN 3 five-year CIR; low-grade cytologya50	14.5 (7.8–26.0)	23.7 (14.8–36.8)	5.1 (2.5–10.4)	1.6 (0.2–10.7)	0
≥CIN 3 ten-year CIR; low-grade cytology50	16.2 (9.0–28.0)	23.7 (14.8–36.8)	5.9 (3.0–11.4)	1.6 (0.2–10.7)	0

^aLow-grade cytology = ASC-US and LSIL combined.